Clinical trials: Refractory Cancer
Acute Myeloid Leukemia (AML)
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
This is a clinical study on the use of iNK cells for the treatment of refractory relapsed acute myeloid leukemia.
- Trial name
- iNK-r/r AML (NCT06702098)
- Testing
- iNK cells
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Guangzhou Ruixin Biotechnological Co., LTD
Neuroblastoma
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
Neuroblastoma, the most common extra-cranial solid tumour in children, remains one of the major challenges in paediatric oncology.
- Trial name
- MiniVan (NCT02914405)
- Testing
- Nivolumab, Ch14.18/CHO
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Lymphoma
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT00568815
- Testing
- Rituximab combined with ESHAP
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Fudan University
Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
This phase I trial is studying the side effects and best dose of alemtuzumab when given together with bendamustine hydrochloride in treating patients with relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
- Conditions
- Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma
- Trial name
- NCT00947388
- Testing
- Bendamustine Hydrochloride, Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute…
- Conditions
- Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
- Trial name
- SCOPE-L (NCT05237258)
- Testing
- Specialty Palliative Care, Primary Palliative Care
- Where
- 20 sites in United States
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma
This phase I trial tests the effect of allogeneic Orca-Q stem cell transplant in treating patients with high-risk multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous…
- Trial name
- NCT07759102
- Testing
- Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Leukemia, B-cell
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety, tolerability, and pharmacokinetic profile of INS19 CAR-T cells for the treatment of patients with relapsed or refractory acute B…
- Trial name
- NCT06209671
- Testing
- INS19 CAR-T Cells
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Non-Hodgkin's Lymphoma
Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma
This aim of this study to evaluate the safety and efficacy of combining a single course of Yttrium 90 Ibritumomab Tiuxetan, a radiolabeled monoclonal antibody ( Zevalin ), with high-dose BEAM chemotherapy and autologous…
- Trial name
- Zevalin (NCT00438581)
- Testing
- Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- McGill University
Lymphoma, Leukemia
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells.
- Trial name
- NCT05237986
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
This phase II MATCH treatment trial tests how well BVD-523FB (ulixertinib) works in treating patients with cancer that has certain genetic changes.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06400225
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory Lymphoma
HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of…
- Trial name
- NCT05720767
- Testing
- HMPL-523, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Hematologic Malignancies
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served.
- Trial name
- NCT01203722
- Testing
- Fludarabine, Cytoxan, Total Body Irradiation
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Preleukemia, Myelodysplastic Neoplasm
Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS
This is a single-arm pilot study of the feasibility and safety of metformin in patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myelodysplastic neoplasms (LR-MDS).
- Conditions
- Preleukemia, Myelodysplastic Neoplasm, Cytopenia, Preleukemic Anemia
- Trial name
- NCT04741945
- Testing
- Metformin
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kirsten Grønbæk
Hodgkin Lymphoma
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Patients with relapsed or refractory Hodgkin Lymphoma who are CD30+ will receive a standard of care reduced intensity regimen and an allogeneic stem cell transplant (from another person, related or unrelated).
- Trial name
- NCT02098512
- Testing
- Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- New York Medical College
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
This is a Phase 3, open-label single-arm trial designed to evaluate the safety and efficacy of NDV-01 (sustained-release gemcitabine-docetaxel) in adult participants with NMIBC with CIS who have failed BCG therapy and who have…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Trial name
- RESCUE (NCT07342517)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Relmada Therapeutics, Inc.
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor peripheral blood stem cells, rather than marrow.
- Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia
- Trial name
- NCT03480360
- Testing
- Cyclophosphamide, Fludarabine, Total Body Irradiation
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Diffuse, Large B-Cell, Lymphoma
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with relapsed/refractory DLBCL.
- Trial name
- GIOTTO (NCT02374424)
- Testing
- GA101_DHAP
- Where
- 10 sites in Italy
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Myelodysplasia, Hematologic Malignancy
Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia
This is a Phase I/II study designed to evaluate the kinetics of hematopoietic reconstitution and the incidence of acute chronic GVHD after partially matched related donor hematopoietic cell transplantation using an αβTCR/CD19+…
- Trial name
- NCT03431090
- Testing
- CliniMACS® TCRαβ/CD19 Combined Depletion System
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital
Ewing Sarcoma
RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
The goal of this clinical research study is to learn if new anticancer drugs or drug combinations can help to control relapsed/refractory ES, DSRCT, or SRCS.
- Trial name
- NCT07781891
- Testing
- LX-101
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor Refractory to Standard Therapy
Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US
This is a single-center, double-blind, single-dose escalation study in healthy volunteers.
- Trial name
- NCT04026321
- Testing
- SQ001 125mL/day, SQ001 250mL/day, SQ001 500mL/day
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.